Filing Details

Accession Number:
0001358403-16-000261
Form Type:
4
Zero Holdings:
No
Publication Time:
2016-09-20 18:19:32
Reporting Period:
2016-09-16
Filing Date:
2016-09-20
Accepted Time:
2016-09-20 18:19:32
SEC Url:
Form 4 Filing
Issuer
Cik Name Symbol Sector (SIC) IRS No
1358403 Bellicum Pharmaceuticals Inc BLCM Pharmaceutical Preparations (2834) 201450200
Insiders
Cik Name Reported Address Insider Title Director Officer Large Shareholder Other
1626895 Ken Moseley C/O Bellicum Pharmaceuticals, Inc.
2130 W. Holcombe Blvd., Ste. 800
Houston TX 77030
Sr. Vp And General Counsel No Yes No No
Reported Non-Derivative Transactions
Sec. Name Acquisiton - Disposition Date Amount Price Remaning Holdings Equity Swap Involved Form Type Code Nature of Ownership Explanation
Common Stock Acquisiton 2016-09-16 700 $7.47 1,044 No 4 M Direct
Common Stock Disposition 2016-09-16 700 $20.00 344 No 4 S Direct
Common Stock Acquisiton 2016-09-19 1,300 $7.47 1,644 No 4 M Direct
Common Stock Disposition 2016-09-19 1,300 $20.01 344 No 4 S Direct
Common Stock Acquisiton 2016-09-20 200 $7.47 544 No 4 M Direct
Common Stock Disposition 2016-09-20 200 $20.00 344 No 4 S Direct
Equity Swap Involved Form Type Code Nature of Ownership Explanation
No 4 M Direct
No 4 S Direct
No 4 M Direct
No 4 S Direct
No 4 M Direct
No 4 S Direct
Reported Derivative Transactions
Sec. Name Sec. Type Acquisiton - Disposition Date Amount Price Amount - 2 Price - 2
Common Stock Stock Option (right to buy) Disposition 2016-09-16 700 $0.00 700 $7.47
Common Stock Stock Option (right to buy) Disposition 2016-09-19 1,300 $0.00 1,300 $7.47
Common Stock Stock Option (right to buy) Disposition 2016-09-20 200 $0.00 200 $7.47
Remaning Holdings Exercise Date Expiration Date Equity Swap Involved Transaction Form Type Transaction Code Nature of Ownership
42,417 2024-11-10 No 4 M Direct
41,117 2024-11-10 No 4 M Direct
40,917 2024-11-10 No 4 M Direct
Footnotes
  1. The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted on March 24, 2015.
  2. The price reported is a weighted average price. These shares were sold in multiple transactions at prices ranging from $20.00 to $20.09. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth above.
  3. 25% of the shares subject to the stock option vest and become exercisable on November 11, 2015, and the remaining shares subject to the stock option vest and become exercisable in 36 equal monthly installments thereafter.